PepGen Inc. (PEPG) Price & Analysis

Compare

224 Followers

PEPG Stock Chart & Stats

$4.89

-$0.11(-3.01%)

At close: Jan 08 4:00 PM EST

$4.89

-$0.11(-3.01%)

Day’s Range― - ―

52-Week Range$0.88 - $8.95

Previous CloseN/A

Volume7.67K

Average Volume (3M)6.68M

Market Cap

$336.13M

Enterprise Value-$20.44M

Total Cash (Recent Filing)$74.65M

Total Debt (Recent Filing)$17.86M

Price to Earnings (P/E)―

Beta1.29

Next Earnings

Nov 06, 2025

EPS Estimate

-0.57

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.70

Shares Outstanding68,737,220

10 Day Avg. Volume930,736

30 Day Avg. Volume6,679,177

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.06

Enterprise Value/Revenue-13.70

Enterprise Value/Gross Profit57.57

Enterprise Value/Ebitda0.22

Forecast

1Y Price Target

$8.67

Price Target Upside77.30% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering6

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentThe transition of clinical sites to FREEDOM2-DM1, a Phase 2 multiple ascending dose study, accelerates the clinical timeline and potentially saves 3-6 months.

Clinical Trial ResultsPepGen's nearly 54% splicing correction sets a new benchmark and strongly suggests that repeat dosing could yield clinically meaningful functional benefit.

Stock Price TargetAn increase in the probability of success to 35% and the target price to $12 reflects confidence in the positive data and financing updates.

Bears Say

Clinical UncertaintyOne patient experienced a transient, reversible renal biomarker elevation, indicating that the program might not be out of the woods yet.

CompetitionPEPG is behind competitors in development, and it remains unclear if an accelerated path will be open.

Safety RisksThe safety profile still needs de-risking due to potential readthrough from the discontinued DMD program, where asymptomatic cases of hypomagnesemia were observed.

PepGen Inc. News

PepGen price target raised to $3 from $1 at BofA

BofA raised the firm’s price target on PepGen (PEPG) to $3 from $1 and keeps an Underperform rating...

11d ago

PEPG

RA Capital discloses increased PepGen stake at 29%

In a regulatory filing, RA Capital disclosed it has increased its stake in PepGen (PEPG) by 9.4M shares...

19d ago

PEPG

PepGen price target raised to $12 from $9 at Stifel

Stifel raised the firm’s price target on PepGen (PEPG) to $12 from $9 and keeps a Buy rating...

25d ago

PEPG

Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!

Investors will find all of the hottest stock market stories for Thursday in the TipRanks’ daily market wrap-up. ...

25d ago

ACN

Unusually active option classes on open September 25th

Unusual total active option classes on open include: PepGen Inc (PEPG), Vanguard S&P 500 (VOO), Ally Financial (ALLY),...

25d ago

ACN

Why Is PepGen Stock (PEPG) Up 125% Today?

PepGen stock surged on Thursday thanks to positive results from a Phase 1 clinical trial. ...

25d ago

PEPG

PepGen price target raised to $9 from $7 at Wedbush

Wedbush raised the firm’s price target on PepGen (PEPG) to $9 from $7 and keeps an Outperform rating...

25d ago

RNA

PEPG

PepGen price target raised to $12 from $8 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on PepGen (PEPG) to $12 from $8 and keeps a Buy...

25d ago

PEPG

PepGen 31.25M share Spot Secondary priced at $3.20

Leerink and Stifel acted as joint book running managers for the offering. Published first on TheFly – the...

25d ago

PEPG

PepGen announces common stock offering, no amount given

PepGen (PEPG) announced that it has commenced an underwritten public offering of its common stock and, in lieu...

25d ago

PEPG

PepGen says FREEDOM clinical study achieves all key objectives

PepGen (PEPG) announced positive clinical data from the 15 mg/kg dose cohort of its ongoing FREEDOM-DM1 Phase 1...

25d ago

PEPG

PepGen Highlights Progress in Therapy for DM1

An update from PepGen Inc. ( ($PEPG) ) is now available. On October 1, 2025, PepGen Inc. updated...

18d ago

PEPG

PepGen Inc. Announces Public Offering Agreement

PepGen Inc. ( ($PEPG) ) just unveiled an update. On September 24, 2025, PepGen Inc. announced an underwriting...

24d ago

PEPG

PepGen Inc. Announces Positive Phase 1 Study Results

PepGen Inc. ( ($PEPG) ) has issued an announcement. On September 24, 2025, PepGen Inc. announced positive results...

25d ago

PEPG

PEPG FAQ

What was PepGen Inc.’s price range in the past 12 months?

PepGen Inc. lowest stock price was $0.88 and its highest was $8.95 in the past 12 months.

What is PepGen Inc.’s market cap?

PepGen Inc.’s market cap is $336.13M.

When is PepGen Inc.’s upcoming earnings report date?

PepGen Inc.’s upcoming earnings report date is Nov 06, 2025 which is in 17 days.

How were PepGen Inc.’s earnings last quarter?

PepGen Inc. released its earnings results on Aug 07, 2025. The company reported -$0.7 earnings per share for the quarter, beating the consensus estimate of -$0.846 by $0.146.

Is PepGen Inc. overvalued?

According to Wall Street analysts PepGen Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does PepGen Inc. pay dividends?

PepGen Inc. does not currently pay dividends.

What is PepGen Inc.’s EPS estimate?

PepGen Inc.’s EPS estimate is -0.57.

How many shares outstanding does PepGen Inc. have?

PepGen Inc. has 68,737,220 shares outstanding.

What happened to PepGen Inc.’s price movement after its last earnings report?

PepGen Inc. reported an EPS of -$0.7 in its last earnings report, beating expectations of -$0.846. Following the earnings report the stock price went down -13.139%.

Which hedge fund is a major shareholder of PepGen Inc.?

Currently, no hedge funds are holding shares in PEPG

PepGen Inc. Stock Smart Score

Neutral

Fundamentals

Return on Equity

-85.69%

Trailing 12-Months

Asset Growth

-47.16%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

PepGen Inc.

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

PepGen Inc. (PEPG) Earnings & Revenues

Historic Earnings Reports

PEPG Stock 12 Month Forecast

Average Price Target

$8.67

▲(77.30% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","9":"$9","18":"$18","4.5":"$4.5","13.5":"$13.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4.5,9,13.5,18],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.71,5.270769230769231,5.831538461538462,6.392307692307693,6.953076923076923,7.5138461538461545,8.074615384615385,8.635384615384616,9.196153846153846,9.756923076923076,10.317692307692308,10.87846153846154,11.439230769230768,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.71,5.014615384615385,5.319230769230769,5.623846153846154,5.928461538461539,6.233076923076923,6.537692307692308,6.842307692307692,7.146923076923077,7.451538461538462,7.756153846153846,8.060769230769232,8.365384615384615,{"y":8.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.71,4.578461538461538,4.446923076923077,4.315384615384615,4.1838461538461535,4.052307692307692,3.920769230769231,3.789230769230769,3.6576923076923076,3.526153846153846,3.3946153846153844,3.263076923076923,3.1315384615384616,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.9,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.91,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.07,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.48,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.97,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.79,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.29,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.15,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.31,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.47,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.32,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.2,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.71,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >